Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday.

Can-Fite BioPharma Stock Performance

NYSE CANF opened at $1.81 on Thursday. Can-Fite BioPharma has a 52 week low of $1.29 and a 52 week high of $4.69. The stock has a market capitalization of $6.41 million, a P/E ratio of -1.01 and a beta of 1.32. The stock has a fifty day moving average of $1.85 and a 200-day moving average of $2.35.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.